A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Anti-proliferative effect after 4 weeks of treatment.
AstraZeneca Faslodex Medical Science Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
9238IL/0065
NCT00093002
June 2004
July 2007
Name | Location |
---|---|
Research Site | Bentonville, Arkansas |
Research Site | Beverly, Massachusetts |
Research Site | Albuquerque, New Mexico |
Research Site | Allentown, Pennsylvania |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |